PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Purchased by PFM Health Sciences LP

PFM Health Sciences LP boosted its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 57.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,011,040 shares of the company’s stock after buying an additional 735,578 shares during the quarter. PFM Health Sciences LP owned 3.89% of PMV Pharmaceuticals worth $2,996,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Sio Capital Management LLC increased its stake in PMV Pharmaceuticals by 18.7% in the 3rd quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company’s stock valued at $4,789,000 after purchasing an additional 505,831 shares in the last quarter. BML Capital Management LLC increased its position in shares of PMV Pharmaceuticals by 29.0% in the third quarter. BML Capital Management LLC now owns 1,688,772 shares of the company’s stock valued at $2,516,000 after buying an additional 379,375 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of PMV Pharmaceuticals by 36.1% in the third quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company’s stock valued at $527,000 after buying an additional 93,809 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of PMV Pharmaceuticals by 570.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock worth $113,000 after buying an additional 59,452 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PMV Pharmaceuticals in the 2nd quarter worth about $101,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Price Performance

PMVP opened at $1.62 on Friday. PMV Pharmaceuticals, Inc. has a 12 month low of $1.40 and a 12 month high of $3.47. The business has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.63. The stock has a market capitalization of $83.84 million, a price-to-earnings ratio of -1.60 and a beta of 1.49.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Equities research analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Tuesday, August 20th. Oppenheimer raised shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research note on Friday, November 8th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, PMV Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $5.80.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.